Mathew, Deepa
Barillas-Cerritos, Julia
Nedeljkovic-Kurepa, Ana
Abraham, Mabel
Taylor, Matthew D.
Deutschman, Clifford S. http://orcid.org/0000-0001-9490-4024
Funding for this research was provided by:
National Institute of General Medical Sciences (GM121102)
Article History
Received: 28 February 2023
Accepted: 18 July 2023
First Online: 7 August 2023
Declarations
:
: All studies were approved by the Institutional Animal Care and Use Committee (IACUC) at the Feinstein Institute for Medical Research (IACUC protocol #2018-32), where the study was conducted, adhered to National Institutes of Health Guidelines and met Animal Research: Reporting In Vivo Experiments (ARRIVE) criteria.
: Not applicable.
: Dr. Deutschman is a consultant to Enlivex Inc, Jerusalem Israel and to Siemens Healthcare Diagnostic Inc, Tarrytown, NY. He is the co-editor of a textbook published by Elsevier Inc and has received royalties. He receives a yearly stipend as Scientific Editor of <i>Critical Care Medicine</i> and is a member of the Editorial Board of <i>Shock</i>. Drs. Deutschman and Taylor have received doses of angiotensin-II (Giapreza) from La Jolla Pharmaceuticals for use in research. These interests were n ot directly applicable to the content of this paper.